• Spin-off finalized within five months following board resolution
• Proposal approved in shareholders’ meeting with 99.9% support
• Company to reaffirm its identity as a pure-play CDMO

INCHEON, South Korea, Nov. 3, 2025 /PRNewswire/ — Samsung Biologics (KRX: 207940.KS) today announced the completion of its spin-off of Samsung Bioepis, reinforcing its strategic focus and business specialization as a leading pure-play Contract Development and Manufacturing Organization (CDMO).

Following approval by its Board of Directors, Samsung Biologics separated its investment and subsidiary management business unit to establish Samsung Epis Holdings. The decision was finalized on November 1, with plans to proceed with registration for the corporate division.

The spin-off was successfully completed within five months of its initial announcement. Since disclosing the plan in May, Samsung Biologics submitted its prospectus in August, received regulatory approval in September, and secured shareholder consent at the Extraordinary General Meeting held on October 17.

The spin-off plan was approved with 99.9% shareholder support, reflecting strong confidence in the company’s strategic direction and reaffirming market trust in the rationale behind the separation.

Trading of Samsung Biologics shares has been temporarily paused until November 21 and will resume on November 24, following the re-listing of Samsung Biologics and the new listing of Samsung Epis Holdings.

With the spin-off complete, Samsung Biologics will accelerate its growth as a pure-play CDMO, anchored on three strategic pillars: expanding production capacity, diversifying its service portfolio, and strengthening its global footprint.

By 2032, the company plans to complete construction of its second Bio Campus, further reinforcing its position as the world’s largest biomanufacturer with a total capacity of 1,324,000 liters. It also aims to broaden its portfolio to include next-generation modalities such as antibody-drug conjugates (ADCs) and organoids.

Currently serving 17 of the world’s top 20 global pharmaceutical companies, Samsung Biologics also plans to extend its reach to the top 40 global biopharma clients, with additional expansion into Japan and the broader Asia-Pacific region.

“Through this spin-off, we have solidified our position as a pure-play CDMO and established a firm foundation for continued global growth,” said John Rim, President and CEO of Samsung Biologics. “We remain committed to strengthening operational excellence and creating enduring value for our clients and the patients they serve.”

About Samsung Biologics

Samsung Biologics (KRX: 207940.KS) is a leading contract development and manufacturing organization (CDMO), offering end-to-end integrated services that range from late discovery to commercial manufacturing.

With a combined biomanufacturing capacity of 784,000 liters across five plants, Samsung Biologics leverages cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics.

By implementing the ExellenS™ framework across its manufacturing network with standardized designs, unified processes, and advanced digitalization, Samsung Biologics ensures plant equivalency and speed for manufacturing continuity.

Samsung Biologics also operates commercial offices in Korea, the U.S., and Japan. Samsung Biologics America supports clients based in the U.S. and Europe, while its Tokyo sales office serves the APAC region.

Samsung Biologics continues to invest in new capabilities to maximize operational and quality excellence, ensuring flexibility and agility for clients. The company is committed to the on-time, in-full delivery of safe, high-quality biomedicines, as well as to making sustainable business decisions for the betterment of society and global health.

For more information, visit https://samsungbiologics.com/. 

Samsung Biologics Media Contact
Claire Kim, Head of Marketing & Global Communications
cair.kim@samsung.com

SHANGHAI, Nov. 3, 2025 /PRNewswire/ — The 37th Annual Transcatheter Cardiovascular Therapeutics (TCT2025) symposium was held grandly in San Francisco, USA, attracting widespread attention from the global cardiovascular community. On the morning of October 28th (local time), during the “Innovation Session: Robotics and AI-Enhanced Interventions,” Dr. Wang Rui, representing the team of Academician Ge Junbo from Zhongshan Hospital Affiliated to Fudan University, presented to the world for the first time the safety and efficacy data from the multicenter randomized controlled trial of China’s independently developed PANVIS STAR Vascular Interventional Surgery Control System. The results were encouraging ——in the field of Percutaneous Coronary Intervention (PCI), the introduction of robotic technology is gradually transforming traditional surgical paradigms.

I. Research Background: Why Robot-Assisted PCI?

In traditional PCI procedures, vascular interventional physicians must wear heavy lead aprons and operate for extended periods under X-ray , facing multiple occupational risks such as an increased incidence of orthopedic and ophthalmic diseases. With the advancement of precision medicine and telemedicine, robot-assisted PCI has become a key pathway to address these challenges. However, most current interventional robots rely on joystick control, making it difficult to simulate physicians’ techniques and operating habits. Additionally, limited compatible instruments restrict their widespread clinical adoption. The emergence of the PANVIS STAR system aims to break through this bottleneck.

II. PANVIS STAR System: Design Innovations and Functional Highlights

Independently developed by Shenzhen Institute of Advanced Biomedical Robot Co., Ltd. (abrobo) , the PANVIS STAR system boasts the following outstanding features:

• Equipped with a globally unique PANVIS COF (Catheter On Finger) intuitive operating system: The controller mimics manual operation, aligning better with physicians’ traditional operating habits and reducing the learning curve.
• Separate sterile cassette design: Supports operation of dual guidewires, dual rapid-exchange devices, and microcatheters, enhancing procedural flexibility.
• Multiple control motion modes: Improves the system’s flexibility and adaptability, suitable for different vascular environments and various operators’ surgical habits.
• Ultra-long travel design: Supports the entire procedural workflow after catheter sheath insertion, possessing pan-vascular compatibility.
• 5G remote operation support: Lays the foundation for performing long-distance remote PCI.

III. CAPTAIN-C Study Design: A Rigorous Multicenter RCT

This prospective, multicenter, randomized controlled trial, led by Principal Investigator Academician Ge Junbo, aimed to evaluate the safety and efficacy of PANVIS STAR in PCI.
Inclusion criteria: Obstructive coronary artery disease, coronary artery stenosis ≥50%, with clinical indication for a single PCI procedure.
Exclusion criteria: Included recent stroke, acute MI within 48 hours, severe comorbidities, and complex coronary anatomy, among others.
The primary endpoint was clinical procedural success, defined as: final TIMI flow grade 3; residual stenosis <30%; and no Major Adverse Cardiovascular Events (MACE) during hospitalization.

IV. Core Results: Safe, Feasible, and Remarkably Effective

The study results showed:
Robotic group: 71 cases; Conventional manual group: 73 cases. There were no significant differences between the two groups in age, gender, underlying diseases (hypertension, hyperlipidemia, diabetes), or clinical diagnosis at admission.
Interventional process and angiographic characteristics: Lesion type, rate of subtotal occlusion lesions, lesion length, and stent length showed no significant differences between groups. Almost all interventions were performed via the transradial approach.
The selected lesions were relatively complex, with B2 and C type lesions exceeding 60% in both groups, and approximately 20% of patients in both groups had subacute STEMI and NSTEMI.

Safety and Efficacy Results:
Clinical success rate: 97.18% in the robotic group.
Robotic technical success: 100%, with no conversions to manual procedure and no device deficiencies.
Remarkable effect in reducing radiation exposure for the primary operator: 97.2% reduction in iatrogenic radiation.
No significant differences were observed between the two groups regarding patient radiation dose and contrast agent volume.
These data not only validate the operational stability of PANVIS STAR in complex coronary lesions but also demonstrate its clear value in reducing physicians’ occupational risks.

V. Innovation and Breakthrough: From “Operable” to “Well-Operable”

The breakthrough of PANVIS STAR lies not only in the technology itself but also in its human-centric ergonomic design philosophy. Its controller simulates the traditional vascular interventional operation mode and techniques, allowing physicians to achieve precise, stable, and remote operation without changing their established habits.

Furthermore, the system supports remote intervention in a 5G environment. A successful remote PCI procedure over a distance of 5,200 kilometers was performed jointly by the team of Academician Ge Junbo and Professor Shen Li from Zhongshan Hospital, Fudan University, along with the team of Director Chen Qingxing (an expert from Zhongshan Hospital assisting in Xinjiang), Director Abulimiti Jamali, and Director Maimaitiaili Tuerxun from Kashi Second People’s Hospital in Xinjiang. This lays a practical foundation for future “cross-hospital,” “cross-regional,” and even “cross-border” PCI surgeries

VI. Clinical Value and Future Prospects

The clinical success of PANVIS STAR signifies that China possesses the capability for independent R&D and clinical translation in the field of interventional robotics. Its pan-vascular compatibility further expands its application prospects in areas such as neurovascular and peripheral vascular interventions.

With the integration of 5G networks and artificial intelligence technologies, future robot-assisted interventions will no longer be limited to “replacing human hands” but will advance towards new stages featuring intelligent navigation, automatic planning, and remote collaboration.

VII. Opening a New Chapter in Precision Intervention

The CAPTAIN-C study is not just a “coming-of-age ceremony” for the PANVIS STAR system; it is a solid step forward for Chinese interventional cardiology in the direction of intelligent and remote procedures. As Academician Ge Junbo’s team stated: “What we pursue is not only technological leadership but also enabling more physicians to perform each procedure safely and efficiently, allowing more patients to benefit from the warmth of technology.”

Media Contact:
Yoyo Wang,
wangluyao@abrobo.com  

HONG KONG, Nov. 3, 2025 /PRNewswire/ — Cango Inc. (NYSE: CANG) (“Cango” or the “Company”) today published its Bitcoin production and mining operations update for October 2025.

Bitcoin Mining Production and Mining Operations Update for October 2025

Paul Yu, CEO and Director of Cango, commented, “In October, we increased our average operating hashrate to over 90%, while our Bitcoin holdings surpassed the 6,000 BTC milestone, reaching a total of just over 6,400 BTC by month-end. These achievements highlight the operational maturity we have attained as we near the one-year mark of our strategic transformation. In October, we announced the termination of our ADR program and the planned direct listing of our ordinary shares on the NYSE, which we expect to complete in November. This further reinforces our commitment to operating as a U.S.-centric organization. We believe these operational and financial milestones put us in a strong position to capture value from emerging opportunities in energy and AI going forward.”

About Cango Inc.

Cango Inc. (NYSE: CANG) is primarily engaged in the Bitcoin mining business, with operations strategically deployed across North America, the Middle East, South America, and East Africa. The Company entered the crypto asset space in November 2024, driven by advancements in blockchain technology, the growing adoption of digital assets, and its commitment to diversifying its business portfolio. In parallel, Cango continues to operate an online international used car export business through AutoCango.com, making it easier for global customers to access high-quality vehicle inventory from China. For more information, please visit: www.cangoonline.com.

Investor Relations Contact

Juliet YE, Head of Communications
Cango Inc.
Email: ir@cangoonline.com 

Christensen Advisory
Tel: +852 2117 0861
Email: cango@christensencomms.com

KUALA LUMPUR, Malaysia, Nov. 3, 2025 /PRNewswire/ — Jasmine Food Corporation today proudly announced the launch of Jasmine Oppa Rice, marking a new milestone as Malaysia’s first local brand to introduce Korean-style rice, specially crafted for authentic Korean dishes.

As K-pop and Korean culture continue to captivate Malaysians, from the music we listen to, the dramas we watch, and the food we love, Jasmine is bringing that passion to the dining table with a rice product that delivers the true taste and texture of Korea.

Jasmine Oppa Rice features a soft, fluffy, and slightly chewy texture that perfectly complements popular Korean favourites like bibimbap, kimchi fried rice, and kimbap. Locally packed, halal, and quality assured, it brings both authenticity and convenience to Malaysians who want to enjoy Korean meals at home.

“Malaysians have embraced the Korean wave in so many ways, and food is a big part of that connection,” said Mr. Alan Kwong, Chief Operating Officer of Jasmine Food Corporation. “With Jasmine Oppa Rice, we’re giving Malaysians a chance to enjoy the real Korean dining experience, even at the comfort of their own homes.”

The launch event took place at TGV Cinemas, 1 Utama, attended by distinguished guests, business partners, media, and influencers. Guests were treated to a showcase of Korean-inspired dishes and a special screening of G-Dragon in Cinema: Übermensh to celebrate the debut of Jasmine Oppa Rice.

Jasmine Oppa Rice is now available at major supermarkets and grocery stores nationwide.

For more information, visit www.jasmine.com.my or follow @JasmineFoodMY on social media.

– ENDS –

About Jasmine Food Corporation

Founded in 1960, Jasmine Food Corporation is Malaysia’s leading rice brand, trusted by generations for its quality, innovation, and commitment to healthy living. From fragrant rice to specialty grains, Jasmine continues to deliver products that celebrate both tradition and modern lifestyle.

• Leading private equity firms FountainVest and CPE join as investors, reflecting strong confidence in SML’s strategic direction and future growth
• SML continues to advance its core capabilities for global brand and retail customers through next-generation innovations, including RFID, Digital Product Passport (DPP), Factory Care Solutions (FCS), and Digital IDs
• The new investors will provide SML with additional resources, capital and relationships for the company to drive innovation, digital integration, geographic expansion and customer-centric growth

HONG KONG, Nov. 3, 2025 /PRNewswire/ — SML Group, a global leader in RFID and brand identification solutions, today announced that FountainVest and CPE have joined as new shareholders. The introduction of these two respected global private equity firms marks a pivotal milestone in the company’s growth journey.

SML is a trusted supply chain and digital transformation partner to the world’s leading apparel and retail brands. The company specialises in delivering innovative end-to-end solutions across RFID, Digital Product Passports (DPP), Factory Care Solutions (FCS), Digital IDs and Tags & Labels, enabling customers to improve inventory accuracy, operational efficiency, sustainability tracking, and future consumer engagement.

With a strong global manufacturing footprint and presence across over 20+ countries, SML combines deep technical expertise with agile execution to support clients throughout their product lifecycle, from concept and packaging to digital integration and analytics. The company’s ongoing investment in R&D and advanced digital solutions continues to position it as a leading innovator within the brand identification and digital intelligence ecosystem.

Following a record-breaking 2024 and a strong performance in 2025 despite global headwinds, SML has expanded its global footprint with new production sites, major client partnerships, and significant advancements in sustainability and innovation through initiatives such as InfuseRFID, Factory Care Solutions, and the upcoming Digital Product Passports (DPP). These achievements demonstrate the strength of SML’s strategy, its people, and its ability to evolve with agility and precision.

The transition will be guided collaboratively by the new shareholders and SML’s leadership team. With deep appreciation for the company’s four-decade legacy, SML enters this new chapter with renewed energy and a clear ambition for global growth.

Investor Confidence and Strategic Alignment

The investment from FountainVest and CPE underscores strong confidence in SML’s long-term trajectory and ongoing transformation within brand identification and digital intelligence.

Together, the investors bring both regional and global expertise, extensive networks, and a shared belief in entrepreneurship, innovation, and long-term value creation.

Leadership Perspectives

Mr. Ignatius K.C. Lau, Chief Executive Officer of SML Group, commented:
“2024 marked the most successful year in our history, and 2025 has continued our growth journey despite global challenges. These milestones reflect the strength of SML’s strategy, the dedication of our people, and our ability to adapt and execute with excellence. The investment from FountainVest and CPE is a powerful validation of what we have built over the last four decades and a catalyst for the next phase. We will continue to evolve with determination – advancing innovation, strengthening leadership, and investing in our people.”

Mr. Rishi Pardal, incoming Chairman of SML Group, noted:
“SML’s greatest strength lies in its people – their creativity, commitment, and customer-first mindset. As we enter this next phase, our focus will remain on attracting and empowering talent, investing in innovation, and preserving our agility to ensure we are well prepared to serve our customers as they embrace a digitally enabled future.”

Mr. Andrew Huang, Managing Director at FountainVest, said:
“We have been following SML for many years, and see tremendous potential in SML’s ongoing transformation. As a founder-led company with an agile, entrepreneurial spirit, SML’s culture of innovation and collaboration reflects values we deeply believe in – integrity, teamwork, and forward-thinking. FountainVest has a deep network across the consumer, retail and industrial sectors, and we are excited for our collaborative partnership with the leadership team to support the company’s next chapter of growth.”

Mr. Hemeng Dong, Managing Director at CPE, added:
“CPE has a broad investment ecosystem from key supply chain to potential customers, we are committed to supporting SML in delivering superior products and integrated digital solutions that enhance lead time, quality, and overall performance. We’ll help the company meet growing demand for RFID, DPP and FCS solutions, explore new opportunities in labels, packaging, and software, and create long-term value for our customers.”

The Road Ahead

SML is accelerating innovation in RFID, Digital Product Passports (DPP), Factory Care Solutions (FCS), and Digital IDs, building on its excellent labels and packaging capabilities. The company’s strategic direction remains focused on growth through enhanced commercial capabilities, innovation, and digital transformation, building a more agile, customer-centric, and globally integrated organisation.

About SML

A global leader in digital identification solutions, such as item-level Radio-Frequency Identification (RFID), SML is shaping the future of brand identification globally with smart, creative and sustainable solutions that elevate brands. With over 40 years of retail expertise, SML combines state-of-the-art technology with innovative design to help brands strengthen their identity, enhance security, and improve operational efficiency from factory to shelf – and beyond. As a global leader in item-level brand identification solutions, SML connects billions of items globally each year, powering data-driven operations and enabling smart and more agile retail.

Operating in 25+ locations across 20+ countries, SML delivers global insights and local expertise through a diverse and customer-focused team. Partnering with 600+ brands worldwide, SML provides scalable, high-quality solutions and ensures precision, sustainability, and consistency at every stage of the supply chain.

Trusted Solutions – Powered by People

For more information, please visit https://www.sml.com/.

About FountainVest

FountainVest Partners is an established, independent private equity firm in Asia. It focuses on long-term investments in industry leaders, partnering closely with management teams to unlock value and drive growth, all while seeking to make a positive impact in the communities in which it works. FountainVest has a strong track record, having completed numerous landmark investments across the globe in multiple sectors, including consumer, industrials, and business services. FountainVest manages assets on behalf of the world’s leading public pensions, sovereign wealth funds, and other institutional investors.

For more information, please visit: www.fountainvest.com  

About CPE

CPE is a leading Asia-based alternative asset manager with a global perspective and approximately US$22 billion in assets under management. Pursuing a long-term vision and value investment strategy, CPE provides innovative investment solutions to leading firms from the following three key sectors – technology and industrial, consumer and healthcare, infrastructure. Currently with successful long-term performance, CPE’s funds under management are supported by over 200 domestic and international institutional investors across North America, Europe, Asia and the Middle East. The core investment team has completed more than 300 investments globally, enabling the firm to accumulate key sector knowledge and a widespread business network. With a solid investment and research process, strong sector expertise and professional portfolio management capabilities, CPE builds long-term relationships with its portfolios in order to drive their value creation and sustainable growth.

For more information, please visit: www.cpe-fund.com

Advisors

Citigroup acted as exclusive financial advisor to FountainVest on the transaction. Jefferies acted as exclusive financial advisor to SML. Goodwin, DLA Piper, and Slaughter and May acted as legal advisors to FountainVest, CPE, and SML, respectively.

For media enquiries, please contact:

Rothman & Roman Group (Public Relations agency)

Diana Estella Peter | diana.estella@rothmanasia.com | +65 8498 9424
Olivia-Mae Tan | oliviamae.tan@rothmanasia.com | +65 9763 3312